Quantcast

Latest PEGylation Stories

2014-09-16 20:27:34

-- PEG-Irinotecan is a novel, long-acting polymer-drug conjugate which inhibits Topo-I associated with solid tumors SHENYANG, China, Sept. 16, 2014 /PRNewswire/ -- 3SBio Inc., ("3SBio") a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd ("JenKem") for the development, manufacturing and...

2014-06-18 04:21:10

-- 3SBio's pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory and tophaceous gout as well as tumor lysis syndrome SHENYANG, China, June 18, 2014 /PRNewswire/ -- 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered...

2014-05-17 00:20:11

SAN FRANCISCO, May 16, 2014 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) is scheduled to present at the upcoming UBS 2014 Global Healthcare Conference in New York at the Sheraton New York Hotel on Tuesday, May 20, 2014 at 2:30 p.m. Eastern time. The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until June 20, 2014....

2014-05-01 16:33:20

SAN FRANCISCO, May 1, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2014 on Wednesday, May 7, 2014, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). The press release and a live audio-only Webcast of the conference call can be...

2014-04-29 16:31:09

Polaris Group Scientific Colleagues from Several University Cancer Centers Present Data at 2014 AACR Meeting in San Diego, CA SAN DIEGO, April 29, 2014 /PRNewswire/ -- Polaris Group collaborating scientists from numerous institutions reported results from preclinical studies at the 2014 annual American Association for Cancer Research (AACR) meeting, which showed that certain non-small cell lung cancers (NSCLC), malignant pleural mesothelioma (MPM) and melanomas are more likely to...

2014-04-02 16:31:56

SAN DIEGO, April 2, 2014 /PRNewswire/ -- Polaris Group announced today that Shaw T. Chen, M.D., Ph.D. has joined Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group) as Executive Vice-President of Regulatory Affairs. Dr. Chen had previously been with the United States (US) Food & Drug Administration (FDA) for over 26 years in new drug development as a primary/supervisory medical staff. His achievements at the FDA included management of new drug review divisions, drafting...

2014-04-02 08:33:17

MOSCOW, April 2, 2014 /PRNewswire/ -- Hepatera Ltd. [http://www.hepatera.ru/?ln=en ] announces initiation of a clinical trial investigating Myrcludex B in chronically HBV infected patients who are also infected with hepatitis delta virus (HDV). Hepatera is financed by Maxwell Biotech Venture Fund [http://www.maxwellbiotech.com ] formed with the participation of RVC [http://www.rusventure.ru/en ] - Russia's government fund of venture capital funds. Hepatera was...

2014-02-19 16:24:58

SAN FRANCISCO, Feb. 19, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2013 on Wednesday, February 26, 2014, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). The press release and a live audio-only Webcast of the...

2014-02-18 04:21:07

- The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A WHIPPANY, N.J., Feb. 18, 2014 /PRNewswire/ -- Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational long-acting site-specific PEGylated recombinant human factor VIII compound BAY 94-9027. The study met its primary objective of protection from bleeds with fewer infusions. In the study, the...

2014-02-02 23:02:36

ResearchMoz include new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019 - Industry Size, Shares, Growth, Trends and Forecast 2019" to its huge collection of research reports. Browse reports in Therapeutic Area - http://www.researchmoz.us/therapeutic-area-market-reports-37.html. Albany, NY (PRWEB) February 02, 2014 “Hepatitis C Therapeutics in Major Developed Markets to 2019 – Outstanding Recent Approvals and Late-Stage Pipeline to...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'